Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBA vs FBA Conditioning for Haploidentical HSCT in High Risk/Refractory AML
NCT03384225Phase 3Unknown
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2016
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cladribine in acute myeloid leukemia (AML) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Cumulative Relapse Rate at 2 years. Status: unknown.
02
Drugs
cladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03384225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03384225.